Predictors of Post-Thrombectomy Cognitive Impairment in Acute Ischemic Stroke Patients
Predictors of Post-Thrombectomy Cognitive Impairment in Acute Ischemic Stroke Patients : a Prospective Cohort Study
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Post-stroke cognitive impairment (PSCI) is a major cause of long-term disability, affecting up to 40% of ischemic stroke survivors. Large vessel occlusion (LVO) strokes, often treated with endovascular thrombectomy (EVT), carry a particularly high risk of cognitive sequelae. While EVT has proven efficacy in improving functional outcomes, its effect on cognitive outcomes remains underexplored.
This prospective observational cohort study will enroll approximately 120 adult patients (≥18 years) with anterior circulation LVO undergoing EVT at Assiut University Hospital. Eligible participants must achieve successful reperfusion (mTICI 2b-3) and provide consent. Patients with severe aphasia, coma, pre-existing dementia, non-ischemic etiologies, or early death (within 72 hours) will be excluded.
Participants will undergo systematic assessment of cognitive function (MoCA-Arabic, Oxford Cognitive Screening if MoCA <26), functional status (mRS, Barthel Index), and mood (HADS-Arabic) at baseline, 3 months, and 6 months. Clinical data (demographics, vascular risk factors, NIHSS, time metrics), procedural details (technique, procedure time, number of passes, anesthesia type, hemodynamic stability, complications), radiological parameters (infarct site and volume, ASPECTS, WMH by Fazekas score, cortical atrophy, microbleeds), and laboratory markers (CRP, ESR, lipid profile, HbA1C, uric acid, D-dimer, CBC) will be collected.
The primary objective is to identify predictors of PSCI at 3-6 months after thrombectomy. Secondary objectives include estimating the prevalence of PSCI in this population and analyzing its association with functional outcomes and depression. Statistical analysis will include univariate and multivariate regression models adjusting for potential confounders such as age, education, and infarct volume.
Ethical approval has been obtained from the Faculty of Medicine, Assiut University Ethics Committee. Written informed consent will be obtained from all participants, and confidentiality will be strictly maintained.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Mohammad Ahmad Korayem
- Phone Number: +201021478054
- Email: Mohammadkorayem@aun.edu.eg
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Adults (≥18 years).
- Acute ischemic stroke due to anterior circulation LVO confirmed by imaging undergoing EVT per guidelines.
- Successful reperfusion (mTICI 2b-3)
- Able to provide consent.
Exclusion Criteria:
- Severe aphasia/coma interfering with cognitive assessment.
- Pre-existing dementia ( using Arabic version of the Short Form of the Informant Questionnaire on Cognitive Decline in the Elderly).
- Non-ischemic etiology.
- Death within 72 hours.
- Refusal to participate in the study.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Postthrombectomy
All patients wgo underwent endovascular thrombectomy under standard care will be assessed for cognitive function at 3 time points
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cognitive impairment after thrombectomy (MoCA)
Time Frame: 3 months (±2 weeks) and 6 months (±2 weeks) post-thrombectomy
|
Cognitive status will be assessed using the Arabic version of the Montreal Cognitive Assessment (MoCA, score range 0-30, with scores <26 indicating impairment).
The primary outcome will be the prevalence of post-stroke cognitive impairment (PSCI) among thrombectomy patients.
|
3 months (±2 weeks) and 6 months (±2 weeks) post-thrombectomy
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Domain-specific cognitive performance (OCS)
Time Frame: 3 months (±2 weeks) and 6 months (±2 weeks) post-thrombectomy
|
For participants scoring <26 on MoCA, the Oxford Cognitive Screen (OCS) will be administered to evaluate specific domains of cognition (attention, executive function, memory, language, visuospatial ability).
|
3 months (±2 weeks) and 6 months (±2 weeks) post-thrombectomy
|
|
Depression and anxiety symptoms (HADS)
Time Frame: 3 months (±2 weeks) and 6 months (±2 weeks) post-thrombectomy
|
Psychological status will be measured using the Hospital Anxiety and Depression Scale (HADS, score range 0-21 per subscale).
Outcomes will include mean scores and prevalence of clinically significant symptoms.
|
3 months (±2 weeks) and 6 months (±2 weeks) post-thrombectomy
|
|
Functional independence (Barthel Index)
Time Frame: 3 months (±2 weeks) and 6 months (±2 weeks) post-thrombectomy
|
Functional status will be assessed using the Barthel Index (score range 0-100).
Higher scores indicate greater independence in activities of daily living.
|
3 months (±2 weeks) and 6 months (±2 weeks) post-thrombectomy
|
|
Global disability (modified Rankin Scale)
Time Frame: 3 months (±2 weeks) and 6 months (±2 weeks) post-thrombectomy
|
Global disability will be measured using the modified Rankin Scale (mRS, score range 0-6, with 0 indicating no symptoms and 6 indicating death).
|
3 months (±2 weeks) and 6 months (±2 weeks) post-thrombectomy
|
|
Infarct volume (DWI MRI)
Time Frame: Within 24-72 hours post-thrombectomy
|
Infarct size will be quantified using diffusion-weighted MRI, measured in milliliters.
|
Within 24-72 hours post-thrombectomy
|
|
White matter hyperintensity (Fazekas score)
Time Frame: Within 24-72 hours post-thrombectomy
|
White matter disease burden will be assessed using the Fazekas score (0-3 scale) on FLAIR MRI
|
Within 24-72 hours post-thrombectomy
|
|
CRP
Time Frame: Within 24-72 hours post-thrombectomy
|
C-reactive protein (CRP, mg/L)
|
Within 24-72 hours post-thrombectomy
|
|
Lipid profile
Time Frame: Within 24-72 hours post-thrombectomy
|
lipid profile (mg/dL)
|
Within 24-72 hours post-thrombectomy
|
|
Ddimer
Time Frame: Within 24-72 hours post-thrombectomy
|
D-dimer (µg/mL)
|
Within 24-72 hours post-thrombectomy
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CogEVT25
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.